$CERS
CERUS CORP

2017 Q3 Form 10-Q Financial Statement

#000156459017021518 Filed on November 03, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3
Revenue $10.80M $10.18M
YoY Change 6.11% 26.48%
Cost Of Revenue $5.350M $5.450M
YoY Change -1.83% -1.98%
Gross Profit $5.449M $4.724M
YoY Change 15.35% 90.1%
Gross Profit Margin 50.47% 46.43%
Selling, General & Admin $12.18M $12.16M
YoY Change 0.16% 11.24%
% of Gross Profit 223.53% 257.43%
Research & Development $7.886M $7.033M
YoY Change 12.13% -8.53%
% of Gross Profit 144.72% 148.88%
Depreciation & Amortization $460.0K $430.0K
YoY Change 6.98% 10.26%
% of Gross Profit 8.44% 9.1%
Operating Expenses $20.12M $19.24M
YoY Change 4.53% 3.07%
Operating Profit -$12.38M -$14.26M
YoY Change -13.16% -11.91%
Interest Expense $1.090M $586.0K
YoY Change 86.01% 16.04%
% of Operating Profit
Other Income/Expense, Net -$986.0K -$533.0K
YoY Change 84.99% -188.69%
Pretax Income -$13.37M -$14.79M
YoY Change -9.63% -5.09%
Income Tax $50.00K -$416.0K
% Of Pretax Income
Net Earnings -$13.42M -$14.38M
YoY Change -6.66% -8.32%
Net Earnings / Revenue -124.28% -141.29%
Basic Earnings Per Share -$0.12 -$0.14
Diluted Earnings Per Share -$0.12 -$0.14
COMMON SHARES
Basic Shares Outstanding 109.8M 102.8M
Diluted Shares Outstanding 109.8M 102.8M

Balance Sheet

Concept 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.60M $81.20M
YoY Change -26.6% -18.61%
Cash & Equivalents $17.24M $12.90M
Short-Term Investments $42.60M $68.30M
Other Short-Term Assets $4.100M $7.200M
YoY Change -43.06% 655.51%
Inventory $14.30M $12.20M
Prepaid Expenses
Receivables $10.50M $7.400M
Other Receivables $0.00 $0.00
Total Short-Term Assets $88.40M $108.0M
YoY Change -18.15% -15.9%
LONG-TERM ASSETS
Property, Plant & Equipment $2.300M $3.200M
YoY Change -28.13% -13.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.400M $2.800M
YoY Change 57.14% 2176.42%
Total Long-Term Assets $8.700M $8.100M
YoY Change 7.41% 19.73%
TOTAL ASSETS
Total Short-Term Assets $88.40M $108.0M
Total Long-Term Assets $8.700M $8.100M
Total Assets $97.10M $116.1M
YoY Change -16.37% -14.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.50M $6.900M
YoY Change 81.16% 1.28%
Accrued Expenses $10.70M $10.20M
YoY Change 4.9% 25.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $5.000M
YoY Change -100.0% 257.14%
Total Short-Term Liabilities $23.90M $22.90M
YoY Change 4.37% 14.97%
LONG-TERM LIABILITIES
Long-Term Debt $29.80M $14.40M
YoY Change 106.94% -21.74%
Other Long-Term Liabilities $6.300M $6.400M
YoY Change -1.56% 426.75%
Total Long-Term Liabilities $36.10M $20.80M
YoY Change 73.56% 1611.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.90M $22.90M
Total Long-Term Liabilities $36.10M $20.80M
Total Liabilities $59.90M $43.80M
YoY Change 36.76% 10.42%
SHAREHOLDERS EQUITY
Retained Earnings -$709.8M
YoY Change
Common Stock $747.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.18M $72.30M
YoY Change
Total Liabilities & Shareholders Equity $97.09M $116.1M
YoY Change -16.38% -14.12%

Cashflow Statement

Concept 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$13.42M -$14.38M
YoY Change -6.66% -8.32%
Depreciation, Depletion And Amortization $460.0K $430.0K
YoY Change 6.98% 10.26%
Cash From Operating Activities -$12.85M -$16.25M
YoY Change -20.92% 37.02%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$240.0K
YoY Change -100.0% 4.35%
Acquisitions
YoY Change
Other Investing Activities -$12.34M $12.76M
YoY Change -196.71% -52.25%
Cash From Investing Activities -$12.33M $12.52M
YoY Change -198.48% -52.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.90M 8.880M
YoY Change 146.62% 700.0%
NET CHANGE
Cash From Operating Activities -12.85M -16.25M
Cash From Investing Activities -12.33M 12.52M
Cash From Financing Activities 21.90M 8.880M
Net Change In Cash -3.280M 5.150M
YoY Change -163.69% -67.28%
FREE CASH FLOW
Cash From Operating Activities -$12.85M -$16.25M
Capital Expenditures $0.00 -$240.0K
Free Cash Flow -$12.85M -$16.01M
YoY Change -19.74% 37.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
112000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97086000
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
746916000
CY2017Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
10797000
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-28000
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-709817000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
37183000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
39907000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-77000
CY2017Q3 us-gaap Interest Expense
InterestExpense
1090000
CY2016Q3 us-gaap Interest Expense
InterestExpense
586000
us-gaap Operating Income Loss
OperatingIncomeLoss
-46343000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-59000
CY2017Q3 us-gaap Gross Profit
GrossProfit
5449000
CY2017Q3 us-gaap Contracts Revenue
ContractsRevenue
2285000
us-gaap Contracts Revenue
ContractsRevenue
261000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
151000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
20116000
us-gaap Operating Expenses
OperatingExpenses
58972000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
106159000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101273000
us-gaap Share Based Compensation
ShareBasedCompensation
7008000
cers Non Cash Tax Expense Benefit From Other Unrealized Gain Loss On Available For Sale Securities
NonCashTaxExpenseBenefitFromOtherUnrealizedGainLossOnAvailableForSaleSecurities
3825000
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
3466000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1647000
cers Increase Decrease In Accrued Liabilities And Other Noncurrent Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities
258000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-42200000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-43818000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
33500000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
5029000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
30000000
us-gaap Interest Expense
InterestExpense
1899000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
104000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
114000
us-gaap Interest Expense
InterestExpense
2122000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53456000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26888000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
103000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 cers Accrual For Manufacturing And Development Payment Liability Noncurrent
AccrualForManufacturingAndDevelopmentPaymentLiabilityNoncurrent
4770000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
103000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
57787000
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
10175000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
149000
CY2016Q4 us-gaap Liabilities
Liabilities
45689000
CY2016Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
6934000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
718299000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-660718000
CY2016Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
12441000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1590000
us-gaap Share Based Compensation
ShareBasedCompensation
5966000
cers Non Cash Interest Expense
NonCashInterestExpense
820000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1394000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103476000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3608000
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109846000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
22507000
CY2016Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12161000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36314000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13368000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
50000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-13418000
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109846000
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13427000
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1359000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-986000
CY2016Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7033000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
19244000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12382000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
13402000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
14690000
CY2016Q3 us-gaap Gross Profit
GrossProfit
4724000
us-gaap Gross Profit
GrossProfit
13926000
us-gaap Gross Profit
GrossProfit
12368000
CY2016Q3 us-gaap Contracts Revenue
ContractsRevenue
261000
us-gaap Contracts Revenue
ContractsRevenue
5380000
CY2017Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7886000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
25927000
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12180000
CY2017Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
50000
CY2016Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
50000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
151000
us-gaap Operating Expenses
OperatingExpenses
65985000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14259000
us-gaap Operating Income Loss
OperatingIncomeLoss
-46679000
CY2016Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-61000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3722000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
293000
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-533000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1541000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1683000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14792000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-45138000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48026000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-416000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3961000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1379000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-14376000
us-gaap Net Income Loss
NetIncomeLoss
-49099000
us-gaap Net Income Loss
NetIncomeLoss
-49405000
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102769000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106159000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101273000
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102769000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
18000
cers Non Cash Interest Expense
NonCashInterestExpense
282000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
19000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1800000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
379000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4022000
cers Increase Decrease In Accrued Liabilities And Other Noncurrent Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherNoncurrentLiabilities
-1477000
cers Increase Decrease In Manufacturing And Development Payment Liability
IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability
600000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
514000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
354000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
50183000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
55566000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2421000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18840000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
19593000
CY2016Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
260000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-131000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4051000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14116000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49230000
CY2016Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
137000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-2126000
cers Non Cash Tax Expense Benefit From Other Unrealized Gain Loss On Available For Sale Securities
NonCashTaxExpenseBenefitFromOtherUnrealizedGainLossOnAvailableForSaleSecurities
1246000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1432000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-354000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1562000
cers Increase Decrease In Manufacturing And Development Payment Liability
IncreaseDecreaseInManufacturingAndDevelopmentPaymentLiability
-3258000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
306000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
359000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
71760000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-38619000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2710000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
22146000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
591000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
31668000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
24265000
cers Cash Cash Equivalents And Restricted Cash Period Increase Decrease
CashCashEquivalentsAndRestrictedCashPeriodIncreaseDecrease
-5503000
cers Cash Cash Equivalents And Restricted Cash Period Increase Decrease
CashCashEquivalentsAndRestrictedCashPeriodIncreaseDecrease
-58172000
CY2016Q4 cers Cash Cash Equivalents And Restricted Cash At Carrying Value
CashCashEquivalentsAndRestrictedCashAtCarryingValue
22744000
CY2015Q4 cers Cash Cash Equivalents And Restricted Cash At Carrying Value
CashCashEquivalentsAndRestrictedCashAtCarryingValue
71630000
CY2017Q3 cers Cash Cash Equivalents And Restricted Cash At Carrying Value
CashCashEquivalentsAndRestrictedCashAtCarryingValue
17241000
CY2016Q3 cers Cash Cash Equivalents And Restricted Cash At Carrying Value
CashCashEquivalentsAndRestrictedCashAtCarryingValue
13458000
CY2016Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
200000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18646000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16027000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to the accounts receivable, inventory reserves, fair values of investments, stock-based compensation, intangible assets and goodwill, useful lives of intangible assets and property and equipment, income taxes, and accrued liabilities, among others. The Company bases its estimates on historical experience, future projections, and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, available-for-sale securities and accounts receivable.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Company&#8217;s investment policy, substantially all of the Company&#8217;s cash, cash equivalents and available-for-sale securities are maintained at major financial institutions of high credit standing. The Company monitors the financial credit worthiness of the issuers of its investments and limits the concentration in individual securities and types of investments that exist within its investment portfolio. Generally, all of the Company&#8217;s investments carry high credit quality ratings, which is in accordance with its investment policy. At September&#160;30, 2017, the Company does not believe there is significant financial risk from non-performance by the issuers of the Company&#8217;s cash equivalents and short-term investments.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of credit risk with respect to trade receivables exist. On a regular basis, including at the time of sale, the Company performs credit evaluations of its significant customers that it expects to sell to on credit terms. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines specific invoices or customer accounts may be uncollectible, the Company establishes an allowance for doubtful accounts against the accounts receivable on its unaudited condensed consolidated balance sheets and records a charge on its unaudited condensed consolidated statements of operations as a component of selling, general and administrative expenses.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had two and three customers that accounted for more than 10% of the Company&#8217;s outstanding trade receivables at September&#160;30, 2017 and&#160;December&#160;31, 2016, respectively. These customers cumulatively represented approximately 42% and 46% of the Company&#8217;s outstanding trade receivables at September&#160;30, 2017 and December&#160;31, 2016, respectively. To date, the Company has not experienced collection difficulties from these customers.</p></div>
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Guarantee and Indemnification Arrangements</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company&#8217;s technology infringes the intellectual property rights of a third party or claims that the sale or use of the Company&#8217;s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally provides for a one-year warranty on certain of its INTERCEPT blood-safety products covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. The Company has not experienced significant or systemic warranty claims nor is it aware of any existing current warranty claims. Accordingly, the Company had not accrued for any future warranty costs for its products at September&#160;30, 2017 and December&#160;31, 2016.</p></div>
CY2017Q3 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2017Q3 cers Cumulative Outstanding Trade Receivables Number Of Major Customers
CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers
2
CY2016Q4 cers Cumulative Outstanding Trade Receivables Number Of Major Customers
CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers
3
cers Inventory Life Finished Goods Period
InventoryLifeFinishedGoodsPeriod
P2Y
cers Work In Process Inventory Life Period
WorkInProcessInventoryLifePeriod
P1Y
CY2017Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
200000
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P10Y
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2017Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18942000
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16555000
cers Product Warranty Term
ProductWarrantyTerm
P1Y
CY2017Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
0
CY2016Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
0
CY2017Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
49276000
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
28000
CY2017Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
49248000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
54131000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3952000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
24000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
58059000
CY2017Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
43261000
CY2017Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2016Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
100000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
200000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
200000
CY2017Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7857000
CY2017Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
8571000
CY2017Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
8572000
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
54131000
CY2017Q3 us-gaap Available For Sale Equity Securities Amortized Cost Basis
AvailableForSaleEquitySecuritiesAmortizedCostBasis
0
CY2016Q4 us-gaap Available For Sale Equity Securities Amortized Cost Basis
AvailableForSaleEquitySecuritiesAmortizedCostBasis
0
CY2017Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
6015000
CY2017Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
43244000
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
54107000
CY2017Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
6004000
CY2017Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
37396000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
40121000
CY2017Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
27000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
24000
CY2017Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
2000000
CY2017Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1000
CY2017Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
39396000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
40121000
CY2017Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
28000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
24000
CY2016Q3 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2017Q3 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
3500000
CY2016Q3 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2017Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3523000
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5044000
CY2017Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
10727000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7487000
CY2017Q3 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0
us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0
CY2017Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2017Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2017000
CY2017Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1430000
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2017000
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1279000
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
100000
CY2017Q3 us-gaap Cost Method Investments
CostMethodInvestments
0
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5546000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7098000
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3454000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2511000
CY2017Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
675000
CY2016Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
476000
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1006000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1133000
CY2017Q3 cers Long Term Debt Maturities Repayments Of Interest
LongTermDebtMaturitiesRepaymentsOfInterest
10041000
CY2017Q3 cers Long Term Debt Maturities Repayments Of Principal And Interest In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInNextTwelveMonths
609000
CY2017Q3 cers Long Term Debt Maturities Repayments Of Principal And Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo
2445000
CY2017Q3 cers Long Term Debt Maturities Repayments Of Principal And Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree
10035000
CY2017Q3 cers Long Term Debt Maturities Repayments Of Principal And Interest In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour
10060000
CY2017Q3 cers Long Term Debt Maturities Repayments Of Principal And Interest In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive
9357000
CY2010 cers Proceeds From Landlord Financing Leasehold Improvement
ProceedsFromLandlordFinancingLeaseholdImprovement
1100000
CY2017Q3 cers Long Term Debt Maturities Repayments Of Principal In Year Six
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix
5000000
CY2017Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2017Q3 cers Longterm Debt Maturities Repayments Of Interest In Next Twelve Months
LongtermDebtMaturitiesRepaymentsOfInterestInNextTwelveMonths
609000
CY2017Q3 cers Long Term Debt Maturities Repayments Of Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo
2445000
CY2017Q3 cers Long Term Debt Maturities Repayments Of Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfInterestInYearThree
2178000
CY2017Q3 cers Long Term Debt Maturities Repayments Of Interest In Year Four
LongTermDebtMaturitiesRepaymentsOfInterestInYearFour
1489000
CY2017Q3 cers Long Term Debt Maturities Repayments Of Interest In Year Five
LongTermDebtMaturitiesRepaymentsOfInterestInYearFive
785000
CY2017Q3 cers Long Term Debt Maturities Repayments Of Interest In Year Six
LongTermDebtMaturitiesRepaymentsOfInterestInYearSix
2535000
CY2017Q3 cers Long Term Debt Maturities Repayments Of Principal And Interest In Year Six
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearSix
7535000
CY2017Q3 cers Long Term Debt Maturities Repayments Of Principal And Interest
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterest
40041000
cers Minimum Term Of Non Cancelable Operating Leases
MinimumTermOfNonCancelableOperatingLeases
P1Y
cers Expiration Of Non Cancelable Operating Leases Maximum Year
ExpirationOfNonCancelableOperatingLeasesMaximumYear
2021
CY2017Q3 cers Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
3000000
CY2017Q3 cers Accrued Leasehold Improvements Current And Accrued Leasehold Improvements Noncurrent
AccruedLeaseholdImprovementsCurrentAndAccruedLeaseholdImprovementsNoncurrent
300000
CY2016Q3 cers Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
4800000
cers Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
9400000
cers Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
11800000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1

Files In Submission

Name View Source Status
0001564590-17-021518-index-headers.html Edgar Link pending
0001564590-17-021518-index.html Edgar Link pending
0001564590-17-021518.txt Edgar Link pending
0001564590-17-021518-xbrl.zip Edgar Link pending
cers-10q_20170930.htm Edgar Link pending
cers-20170930.xml Edgar Link completed
cers-20170930.xsd Edgar Link pending
cers-20170930_cal.xml Edgar Link unprocessable
cers-20170930_def.xml Edgar Link unprocessable
cers-20170930_lab.xml Edgar Link unprocessable
cers-20170930_pre.xml Edgar Link unprocessable
cers-ex102_263.htm Edgar Link pending
cers-ex103_264.htm Edgar Link pending
cers-ex311_14.htm Edgar Link pending
cers-ex312_12.htm Edgar Link pending
cers-ex321_13.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending